News Release Details

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced the appointment of Stephen H. Lang as Vice President, Commercial Operations.

“Steve’s broad knowledge of ophthalmology and experience in building and leading commercial teams in the U.S. along with his global experience are invaluable assets to us”

Lang has more than 30 years of experience in the ophthalmic pharmaceutical industry, specializing in the areas of sales, marketing, sales operations and business development.

“Steve’s broad knowledge of ophthalmology and experience in building and leading commercial teams in the U.S. along with his global experience are invaluable assets to us,” said Daniel White, president and CEO. “He will be a very important part of the leadership team we are building at Clearside Biomedical.”

Lang served from 2006 until 2012 as Vice President, Sales, at ISTA Pharmaceuticals, Inc., where he led the building and expansion of ISTA’s sales organization and exceeded US $160 million in annual sales.

Prior to joining ISTA, Lang was Senior Vice President, U.S. Sales and Marketing, for Novartis Ophthalmics, Inc., where his team launched Visudyne® (Valeant Pharmaceuticals International, Inc.; NYSE: VRX). Visudyne® was the first available drug therapy for people with a form of age-related macular degeneration known as classic "wet AMD." Before joining Novartis, Lang served for more than 16 years in various positions with Allergan, Inc. (NYSE: AGN), including sales, marketing, national accounts and global business development. He obtained his B.B.A. in Management from Georgia Southern University.

“I look forward to helping bring Clearside’s breakthrough products to market,” said Lang, noting that the company’s CLS1001 (triamcinolone acetonide) Suprachoroidal Injectable Suspension is being developed to treat sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. “Using our proprietary microinjection platform to deliver drugs to the back of the eye via the suprachoroidal space holds great promise to help millions of people suffering from debilitating eye diseases. We offer a novel approach to posterior segment care that will be the foundation of Clearside’s commercial success.”

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage ophthalmic pharmaceutical company that develops and commercializes targeted therapeutics to treat sight-threatening diseases. Clearside treats the pathological changes to the blood retinal barrier that lead to retinal blindness by delivering therapeutics through the suprachoroidal space to the retina and choroid using a proprietary microinjection dosage form. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise. This team strives for better delivery and performance of its therapeutic agents to improve the standard of care for patients with retinal and choroidal disease. Visit www.clearsidebiomedical.com for more information.